Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

AIM: Ipilimumab is a fully human, monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4. The objective of the present study was to characterize the clinical pharmacology profile of ipilimumab using a population pharmacokinetic (PPK) approach. METHODS: The PPK model was developed using 209...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yan, Masson, Eric, Dai, David, Parker, Susan M, Berman, David, Roy, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2014
Materias:
Pharmacokinetic Dynamic Relationships
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168385/
https://www.ncbi.nlm.nih.gov/pubmed/24433434
http://dx.doi.org/10.1111/bcp.12323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168385/
https://www.ncbi.nlm.nih.gov/pubmed/24433434
http://dx.doi.org/10.1111/bcp.12323

Ejemplares similares